Synthetic and Crystallographic Studies of a New Inhibitor Series Targeting <i>Bacillus anthracis</i> Dihydrofolate Reductase
作者:Jennifer M. Beierlein、Kathleen M. Frey、David B. Bolstad、Phillip M. Pelphrey、Tammy M. Joska、Adrienne E. Smith、Nigel D. Priestley、Dennis L. Wright、Amy C. Anderson
DOI:10.1021/jm800776a
日期:2008.12.11
of resistance have produced a compelling need for new therapeutic agents against this organism. Bacillus anthracis is known to be insensitive to the clinically used antifolate, trimethoprim, because of a lack of potency against the dihydrofolatereductase enzyme. Herein, we describe a novel lead series of B. anthracis dihydrofolatereductaseinhibitors characterized by an extended trimethoprim-like scaffold
炭疽芽孢杆菌是炭疽病的病原体,具有重大的生物防御危险。批准的治疗方法的严重限制和耐药性的产生已经产生了对针对这种生物的新治疗剂的迫切需求。已知炭疽芽孢杆菌对临床使用的抗叶酸甲氧苄啶不敏感,因为它对二氢叶酸还原酶缺乏效力。在此,我们描述了一种新型先导系列炭疽芽孢杆菌二氢叶酸还原酶抑制剂,其特征是扩展的甲氧苄啶样支架。最好的先导化合物的分子量仅增加 22 Da,其效力是甲氧苄啶的 82 倍。该先导化合物在 NADPH 存在下与炭疽芽孢杆菌二氢叶酸还原酶结合的 X 射线晶体结构被确定为 2.25 A 分辨率。